Omeros (OMER)
(Delayed Data from NSDQ)
$3.36 USD
+0.04 (1.20%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.36 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Brokerage Reports
Omeros Corporation [OMER]
Reports for Purchase
Showing records 261 - 280 ( 423 total )
Company: Omeros Corporation
Industry: Medical - Products
May and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Q1 Financials Not Material in Front of Imminent OMIDRIA PDUFA Decision; Reiterate OUTPERFORM and $37 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 14
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
April and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
2013 Financials In-Line. Recent Financings Provide Runway Into 2015 and Cover Major 2014 Catalysts. Reiterate OUTPERFORM and Increasing to $37 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
2013 Financials In-Line. Recent Financings Provide Runway Into 2015 and Cover Major 2014 Catalysts. Reiterate OUTPERFORM and Increasing to $37 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
February and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Positive OMS824 Phase 2a Results in Schizophrenia Warrant Further Development in Multiple Neuropsychiatric Disorders; Reiterate OUTPERFORM and $32 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Company: Omeros Corporation
Industry: Medical - Products
Potentially Transforming Catalysts Make OMER One of Our Top Picks for 2014; Reiterating OUTPERFORM and $32 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Omeros Corporation
Industry: Medical - Products
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L